PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Prices as of the 2026-10-02 close
Future Medicine faces full capital impairment even as an offshore private fund becomes its new controlling shareholder, with the US late-stage Phase 2 trial of MASH candidate FM101 emerging as the company's pivotal test.
2025 total equity stood at negative KRW 3.54 billion, marking four straight years of full capital impairment
A combined KRW 10.7 billion third-party share placement to NK Therapeutics Corp and Tribeca Global SPAC Fund IV triggered a change of controlling shareholder
Lead pipeline FM101 for MASH is advancing toward a US late-stage Phase 2b trial starting in 2026
Obesity candidate FM801 remains preclinical, with the company seeking early out-licensing
A KOSDAQ transfer listing remains unconfirmed despite an A-grade technology assessment obtained around 2023, following a prior withdrawal and repeated attempts
Founded in 2015, Future Medicine is a drug discovery company that identifies candidates through its proprietary nucleoside-derivative platform, FOCUS.
The company has no product sales and instead relies on out-licensing of clinical- and preclinical-stage pipeline assets to global pharmaceutical customers who in-license and commercialize the technology.
Its flagship candidate is FM101, a treatment for non-alcoholic steatohepatitis (NASH/MASH) that targets the A3 adenosine receptor to suppress both inflammation and fibrosis. FM101's Korea and China rights were out-licensed to HK inno.N in 2020, and the compound is currently in global Phase 2 trials in Europe and Korea.
Additional preclinical assets include the targeted oncology candidate FM301 (a Haspin kinase inhibitor), antiviral FM203, immuno-oncology candidate FM401, and autoimmune-disease candidate FM503, with collaboration partners including Arontier and GI Innovation.
The company recently added an obesity candidate, FM801, which simultaneously modulates the A2A and A3 adenosine receptors, to strengthen its metabolic-disease pipeline.
With roughly 26 employees, the company remains a small research-focused organization headquartered at Pangyo Technovalley 2 in Seongnam, Gyeonggi Province.
| Quarter | Revenue | Operating profit | Op. margin |
|---|
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | — | -₩8B | -₩7.3B | — | −634.0% | 394.3% |
| 2023 | — | -₩6.3B | -₩6.1B | — | −318.0% | 238.2% |
| 2024 | — | -₩4.1B | -₩4B | — | — | −212.5% |
| 2025 | — | -₩1.6B | -₩1.6B | — | — | −119.0% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-12
Consolidated operating loss for 2025 was KRW 1.63 billion, sharply narrower than the KRW 4.09 billion loss recorded in 2024, and net loss attributable to owners also shrank to KRW 1.63 billion from KRW 3.99 billion in 2024.
This continues a three-year trend of narrowing losses, following operating losses of KRW 6.27 billion in 2023 and KRW 8.05 billion in 2022. The narrowing appears driven more by cost containment, including R&D spending, than by revenue growth, as no revenue figure is disclosed in the financial data.
Operating cash flow also improved, from negative KRW 7.32 billion in 2022 to negative KRW 1.18 billion in 2025, though the company continues to burn cash each year.
Total equity was positive at KRW 1.15 billion in 2022 and KRW 1.91 billion in 2023, but turned to full capital impairment at negative KRW 1.93 billion in 2024 and deepened further to negative KRW 3.54 billion in 2025. Total liabilities have stayed relatively stable in the KRW 4.1-4.5 billion range across 2022-2025.
Loss per share also narrowed, reflecting both the reduced net loss and the increase in shares outstanding from capital raises. For the trailing four quarters (2025 Q1-Q4), the cumulative net loss attributable to owners matches the full-year figure of KRW 1.63 billion.
The global MASH (metabolic dysfunction-associated steatohepatitis) treatment market is expanding rapidly as GLP-1-class obesity drugs gain MASH indications. GlobalData market research had projected the worldwide NASH treatment market to reach roughly $25.3 billion around 2026.
Even so, liver fibrosis that progresses after steatohepatitis remains a key unmet medical need, with existing therapies seen as insufficiently able to halt fibrosis progression.
Against this backdrop, global pharma has pursued acquisitions and licensing deals for MASH fibrosis candidates, including Novo Nordisk's acquisition of Akero Therapeutics and Roche's merger agreement with 89bio.
Domestically, multiple companies including Yuhan (partnered with Boehringer Ingelheim), Dong-A ST's subsidiary Metavia, D&D Pharmatech, and Ildong Pharmaceutical are developing MASH pipelines, and Olix signed a MASH licensing deal with Eli Lilly worth roughly KRW 911.6 billion.
Future Medicine competes in this landscape with an adenosine-receptor-targeting anti-inflammatory and anti-fibrotic mechanism, seeking differentiation based on ELF fibrosis biomarker data obtained from its Phase 2a trial.
However, as a small KONEX-listed drug developer, the company faces structural constraints in self-funding large-scale trials and relies heavily on external capital.
The company has disclosed plans to advance FM101 into a US late-stage Phase 2b trial for MASH patients starting in 2026. To fund this, it approved two rounds of third-party share placements totaling roughly KRW 10.7 billion in December 2025, with proceeds earmarked for the US clinical R&D program.
Management has previously stated a goal of accelerating out-licensing around the time Phase 2 results become clear, and in a 2024-era interview cited an upfront payment target above KRW 100 billion, though this remains an unconfirmed company aspiration rather than a signed deal.
Obesity candidate FM801 is undergoing preclinical work under a Korea Drug Development Fund (KDDF) program, with the company seeking rapid clinical entry and early out-licensing once preclinical studies conclude.
A KOSDAQ transfer listing, for which the company regained an A-grade technology assessment around 2023, has seen its timing repeatedly adjusted given market conditions, and as of 2026 neither renewed pursuit nor a firm schedule has been confirmed.
Separately, a governance shift is underway as NK Therapeutics Corp became the new controlling shareholder following the January 2026 share placement, with the newly issued shares subject to a one-year lock-up from the listing date.
Future Medicine has continued to post net losses through the trailing four quarters, making conventional earnings-based valuation metrics difficult to apply.
Two consecutive years of full capital impairment undermine any traditional net-asset-based valuation yardstick, suggesting the market is pricing the stock more on pipeline and licensing expectations than on book value.
Given the KONEX market's characteristically low liquidity and small market capitalization, direct comparison with KOSDAQ-listed biotech peers has limitations. With no dividend history, dividend-related metrics are not applicable either.
While operating and net losses have narrowed over multiple years, whether this trend leads to resolving the capital impairment or achieving profitability depends on future licensing outcomes and additional financing.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-12
FM101 obtained fibrosis biomarker (ELF) improvement data in its Phase 2a trial, and the company has disclosed plans to advance to a US late-stage Phase 2b trial in 2026. The broader industry backdrop, marked by continued acquisitions and licensing of MASH fibrosis candidates by global pharma, is also supportive.
An existing Korea/China licensing relationship with HK inno.N provides an established development partnership base.
Operating losses narrowed for three consecutive years, from roughly KRW 8 billion in 2022 to roughly KRW 1.6 billion in 2025, and operating cash outflow shrank substantially over the same period. Cost-control efforts have contributed to one aspect of the financial improvement.
Beyond FM101, the company holds several other candidates including oncology asset FM301, antiviral FM203, immuno-oncology asset FM401, and obesity candidate FM801, which partly diversifies single-asset failure risk.
Collaborative research arrangements with external partners such as Arontier and GI Innovation are also in place.
Total equity deteriorated from negative KRW 1.93 billion in 2024 to negative KRW 3.54 billion in 2025, with the impairment gap widening. Total liabilities have remained largely unchanged in the KRW 4.2-4.5 billion range, delaying any recovery in financial soundness.
Two third-party share placements in December 2025 raised roughly KRW 10.7 billion in total, resulting in an offshore private fund becoming the controlling shareholder. The business appears structurally dependent on continued external financing, and the governance change adds uncertainty to future management direction.
No revenue figure is confirmed in the disclosed financial data, and the company's primary revenue model of large-scale out-licensing has not yet materialized at scale.
FM101 patient recruitment was previously delayed, adjusting the clinical timeline, and a government-funded glaucoma treatment development project was discontinued for reasons unrelated to technical feasibility, warranting scrutiny of pipeline execution capability.
Full capital impairment has persisted for two consecutive years, and the company continues to burn cash annually with no revenue. Delays in additional capital raises or external investment could pose challenges to business continuity.
Results from lead asset FM101's late-stage Phase 2 trial are not yet available, and any trial failure or delay could significantly undermine licensing expectations that represent a substantial portion of the company's perceived value. Licensing negotiations typically take extended periods, with deal terms and outcomes uncertain.
The change of controlling shareholder to an offshore private fund could shift management direction or strategic priorities. The KONEX market's characteristically low trading volume and liquidity is another factor that can amplify price volatility.
Watch for disclosures on the initiation of FM101's US late-stage Phase 2b trial and first patient dosing.
Check for progress on the FM101 out-licensing negotiations the company has targeted, and whether any deal is finalized.
Assess whether the capital impairment persists or is resolved, and monitor any further capital raise or financing plans.
The one-year lock-up on shares issued in January 2026 expires around this time, so watch for any change in the controlling shareholder's stake.
Watch for any disclosure confirming renewed pursuit of a KOSDAQ transfer listing and a preliminary review filing schedule.
Future Medicine is a small KONEX-listed drug developer whose business model relies on out-licensing rather than product sales; its 2025 results showed an operating loss of KRW 1.63 billion and a net loss attributable to owners of KRW 1.63 billion, continuing a multi-year trend of narrowing losses.
However, total equity has been in full capital impairment for two consecutive years, deepening to negative KRW 3.54 billion at the end of 2025.
Amid this financial fragility, the company raised roughly KRW 10.7 billion through two third-party share placements in December 2025, resulting in offshore private fund NK Therapeutics Corp becoming the controlling shareholder in January 2026.
The company's pivotal test is whether its MASH candidate FM101 successfully advances into a US late-stage Phase 2b trial and secures a licensing deal, both of which remain unconfirmed future events.
Follow-on pipeline assets including obesity candidate FM801 remain preclinical, suggesting considerable time and capital will still be needed before commercialization. Investors should weigh three factors in balance: financial fragility, clinical/licensing uncertainty, and the ongoing governance transition.
Report written 2026-09-12 · Data as of 2026-09-11
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.